富蘭克林坦伯頓全球投資系列-生技領航基金美元A(acc)股
43.35美元0.47(1.07%)
2024/09/06更新
績效 / 1月4.61%
3月5.41%
1年29.3%
晨星評等 - 1.現金0.76%
- 2.股票13.27%
- 3.債券0.00%
- 4.其他85.97%
- 1.美國84.44%
- 2.歐洲不包含歐元區4.62%
- 3.歐元區4.48%
- 4.英國3.30%
- 5.加拿大0.73%
- 1.Amgen Inc8.19%
- 2.Regeneron Pharmaceuticals Inc7.14%
- 3.Vertex Pharmaceuticals Inc6.04%
- 4.Insmed Inc3.76%
- 5.Ascendis Pharma A/S ADR3.62%
- 6.Gilead Sciences Inc3.27%
- 7.Intra-Cellular Therapies Inc2.97%
- 8.Biogen Inc2.93%
- 9.AstraZeneca PLC ADR2.85%
- 10.Merus NV2.82%
- 1.現金0.76%
- 2.股票13.27%
- 3.債券0.00%
- 4.其他85.97%
- 1.美國84.44%
- 2.歐洲不包含歐元區4.62%
- 3.歐元區4.48%
- 4.英國3.30%
- 5.加拿大0.73%
- 1.Amgen Inc8.19%
- 2.Regeneron Pharmaceuticals Inc7.14%
- 3.Vertex Pharmaceuticals Inc6.04%
- 4.Insmed Inc3.76%
- 5.Ascendis Pharma A/S ADR3.62%
- 6.Gilead Sciences Inc3.27%
- 7.Intra-Cellular Therapies Inc2.97%
- 8.Biogen Inc2.93%
- 9.AstraZeneca PLC ADR2.85%
- 10.Merus NV2.82%